Greene, J., Nguyen, A., Bagby, S. M., Jones, G. N., Tai, W., Quackenbush, K. S., . . . Arcaroli, J. J. (2017). The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. Oncotarget.
Styl ChicagoGreene, Justin, et al. "The Novel ATM Inhibitor (AZ31) Enhances Antitumor Activity in Patient Derived Xenografts That Are Resistant to Irinotecan Monotherapy." Oncotarget 2017.
Citace podle MLAGreene, Justin, et al. "The Novel ATM Inhibitor (AZ31) Enhances Antitumor Activity in Patient Derived Xenografts That Are Resistant to Irinotecan Monotherapy." Oncotarget 2017.
Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..